75 STATE STREET, BOSTON, MA
CFO Departure - Lori Firmani Steps Down at Damora Therapeutics
Damora Therapeutics Dismisses EY Denmark as Independent Auditor
Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Earnings Release
Underwriting Agreement with Jefferies and Leerink for $295.9M Offering
Departure of CEO Hans T. Schambye Effective February 10, 2026
Investor Presentation
Warrant Issuance to Paramora for 628,302 Shares at $23.01 Each
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Notice of Proposed Sale of Securities
Submission Upload
Correspondence